DEA Proposes to Amend Procedures for Controlled Substance Quotas in Crackdown on Diversion
The Drug Enforcement Administration is proposing to amend its procedures for setting and applying for production and procurement quotas for schedule I and II controlled substances. The agency’s proposed rule would update provisions on the information considered by DEA, in…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
particular directing consideration of the extent of diversion of the controlled substance, when it sets and adjusts aggregate and individual production quotas. DEA would also be able to require additional information from applicants for manufacturing and production quotas that may help to detect or prevent diversion, including customer identities and the amounts of the controlled substance sold to each customer. The measures would help DEA address the ongoing opioid addiction crisis, DEA said. “It’s a common sense idea: the more a drug is diverted, the more its production should be limited,” Attorney General Jeff Sessions said in a press release announcing the proposed rule. DEA hopes to have its final regulations in place for the 2019 quota process, the agency said in the proposal. Comments are due May 4.